Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Celebrating the hard work and dedication of our wonderful Talent Manager

For those who follow Porterhouse Medical Group on social media and keep an eye on the News & Views section of our website, you will be aware that we have...

Porterhouse Medical Group

- PMLiVE

Keytruda growth helps Merck to offset COVID-19 impact in Q3

Profits beat expectations in the third quarter of 2020

- PMLiVE

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

Data monitoring committee has not yet conducted any interim efficacy analysis of the shot

- PMLiVE

Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures

Earnings were particularly impacted by lower demand for top diabetes drug Trulicity

- PMLiVE

Warren Buffett’s greatest health lesson

He told us about it almost two decades ago – we didn’t pay attention

- PMLiVE

COVID-19 vaccine developers won’t face pre-approval FDA inspections for EUAs

Companies typically face inspections before gaining approval from the FDA

- PMLiVE

Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE

Researchers say COVID-19 antibody levels have fallen rapidly in the UK

Number of people testing positive for antibodies fell by 26.5% between June and September

- PMLiVE

Eli Lilly ends COVID-19 antibody trial in hospitalised setting, other studies continue

Bamlanivimab is being studied in a number of additional ongoing trials

- PMLiVE

Exploring the potential of eosinophils

GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils

Eliminating pharmaceutical rebates, is this déjà vu?

By Andrew Parece and Matthew Majewski

AstraZeneca AZ

AZ’s COVID-19 vaccine shows promise in younger and older adults

Company said vaccine produces similar immune response in younger and older adults

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links